Global Molecular Diagnostics Market To Reach $7.3B By 2019
The global molecular diagnostics market will grow by $2.4 billion over the next five years according to a global market report from Medtech Insight. Major factors contributing to the healthy growth of this market include advances in technology, as well as the growing understanding of the human genome, pharmacogenomics and the relationship between genes and disease/infection.
You may also be interested in...
Danaher Buys Cepheid For $4bn, Citing Molecular Diagnostics Strength
Danaher is paying a 54% premium to acquire Cepheid, maker of the fully automated GeneXpert rapid genetic testing system. Cepheid will join Danaher's $5bn Diagnostics segment, which already includes Beckman Coulter, Leica Biosystems and Radiometer. Danaher executives cited Cepheid's large installed base and potential for growth and efficiency improvements as justifications for the deal. At least one analyst believes Danaher may be paying too much.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.
UK Aims To Quadruple Patient Recruitment To Industry Clinical Trials By 2027
The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service.